A single blind, placebo-controlled randomized study of the safety, reactogenicity and immunogenicity of the “EpiVacCorona” Vaccine for the prevention of COVID-19, in volunteers aged 18–60 years (phase I–II)
Russian Journal of Infection and Immunity (2021) - Comments
doi: 10.15789/2220-7619-asb-1699  issn: 2313-7398  issn: 2220-7619 

A. B. Ryzhikov, Е. А. Ryzhikov, M. P. Bogryantseva, S. V. Usova, E. D. Danilenko, E. A. Nechaeva, O. V. Pyankov, O. G. Pyankova, A. S. Gudymo, S. A. Bodnev, G. S. Onkhonova, E. S. Sleptsova, V. I. Kuzubov, N. N. Ryndyuk, Z. I. Ginko, V. N. Petrov, A. A. Moiseeva, P. Yu. Torzhkova, S. A. Pyankov, T. V. Tregubchak